Seminars in Pediatric Neurology
Volume 13, Issue 4 , Pages 271-278 , December 2006

Management of the Child With Weakness

  • Brenda L. Wong, MBBS, MRCP

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Brenda L Wong, MBBS, MRCP, Department of Pediatrics, Division of Pediatric Neurology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH 45229-3039.

References 

  1. Steele R. Experiences of families in which a child has a prolonged terminal illness: modifying factors. Int J Palliat Nurs. 2002;8:418–434
  2. Kishnani P, Spencer C, Byrne B, et al. Long term efficacy of enzyme replacement therapy (ERT) in children with Pompe disease. 2006;[Abstract] ACMG 2006 meeting, March 22-26, San Diego, CA
  3. Hughes RAC, Wijdicks EFM, Barohn R, et al. Practice parameter: immunotherapy for Guillan-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61:736–740
  4. Hughes RAC, Raphael JC, Swan AV, et al. Intravenous immunoglobulin for Guillan-Barr, syndrome (Cochrane Review) (The Cochrane Library Issue 2). Oxford: Update Software; 2002;
  5. Hughes RAC, van der Mech FGA. Corticosteroids for Guillan-Barr, syndrome (Cochrane Review) (The Cochrane Library Issue 2). Oxford: Update Software; 2002;
  6. Mastaglia FL. Neuromuscular disorders: Molecular and therapeutic insights. Lancet Neurol. 2005;4:6–7
  7. Wong BLY, Glauser TA. Single high-dose intravenous immunoglobulin for treatment of pediatric Guillain Barr, Syndrome. J Child Neurol. 1998;13:146
  8. van Koningsveld R, Schmitz PIM, van der Mech A, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr, syndrome: Randomised trial. Lancet. 2004;363:192–196
  9. Shahar E. Current therapeutic options in severe Guillan-Barr, syndrome. Clin Neuropharmacol. 2006;29:45–51
  10. Chadehumbe M, Dinopolous A, Wong B: Steroids and IVIG in EBV-related Pediatric Guillain Barr, Syndrome [abstract]. 10th International Child Neurology Congress, June 12-16, 2006, Montreal, Canada
  11. Arakawa H, Yuhara Y, Todokoro M, et al. Immunoadsorption therapy for a child with Guillan-Barr, syndrome subsequent to Mycoplasma infection: A case study. Brain Dev. 2005;27:431–433
  12. Ropper AH. Current treatments for CIDP. Neurology. 2003;60(suppl 3):S16–S22
  13. Nevo Y, Topaloglu H. 88th ENMC International Workshop: Childhood chronic inflammatory demyelinating polyneuropathy (including revised diagnostic criteria). Naarden, The Netherlands, December 8-10, 2000 Neuromuscul Disord. 2002;12:195–200
  14. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology. 2003;61:1652–1661
  15. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2003;2:CD002277
  16. Schneider-Gold C, Gajdos P, Toyks KV. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;2:CD002828
  17. Kattach H, Anastasiadis K, Cleuziou J, et al. Transsternal thymectomy for myasthenia gravis: Surgical outcome. Ann Thorac Surg. 2006;81:305–308
  18. Essa M, El-Medany Y, Hajjar W, et al. Maximal thymectomy in children with myasthenia gravis. Eur J Cardiothorac Surg. 2003;24:187–189
  19. Seguier-Lipszyc E, Bonnard A, Evrard P, et al. Left thoracoscopic thymectomy in children. Surg Endosc. 2005;19:140–142
  20. Engel AG, Ohno K, Sine SM. Congenital myasthenic syndromes: Progress over the past decade. Muscle Nerve. 2003;27:4–25
  21. Harper CM, Fukudome T, Engel AG. Treatment of slow channel congenital myasthenic syndrome with fluoxetine. Neurology. 2003;60:170–173
  22. Beeson D, Hantai D, Lochmuller H, Engel AG. 126th International Workshop: Congenital Myasthenic Syndromes, 24-26 September 2004, Naarden, The Netherlands. Neuromuscul Disord. 2005;15:498–512
  23. Dalakas M. Therapeutic targets in patients with inflammatory myopathies: Present approaches and a look to the future. Neuromuscul Disord. 2006;16:223–236
  24. Moxley RT, Ashwal S, Pandya S, et al. Practice Parameter: Corticosteroid treatment of Duchenne dystrophy. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005;64:13–20
  25. Manzur AY, Kuntzer T, Pike M, et al. A glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Rev. 2004;2:1–55
  26. Hahn BH, Pletscher S, Muniain M. Immunosuppressive effects of deflazacort—A new glucocorticoid with bone-sparing and carbohydrate-sparing properties: Comparison with prednisone. J Rheumatol. 1981;6:783–790
  27. Bonifati MD, Ruzza G, Bonnometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne dystrophy. Muscle Nerve. 2000;23:1344–1347
  28. Biggar WD, Harris VA, Eliasoph L, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16:249–255
  29. Eagle M, McCallum M, Blyth S, et al. The impact of corticosteroids on forced vital capacity in Duchenne muscular dystrophy. Neuromuscul Disord. 2005;15:689;(abstr)
  30. Biggar WD, Harris VA, Campbell KA, et al. Improved pulmonary function in boys with Duchenne muscular dystrophy when deflazacort treatment is started in the second decade. Neuromuscul Disord. 2005;15:689–690(abstr)
  31. Angelini C, Fanin M, Menegazzo E, et al. Homozygous alpha-sarcoglycan mutation in two siblings: One asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient. Muscle Nerve. 1998;21:769–775
  32. Eagle M. Report on the Muscular Dystrophy Campaign Workshop: Exercise in neuromuscular diseases Newcastle, January 2002. Neuromuscul Disord. 2002;12:975–983
  33. Sutherland DH, Olsen R, Cooper L, et al. The pathomechanics of gait in Duchenne muscular dystrophy. Dev Med Child Neurol. 1981;23:3–22
  34. Khodadadeh S, McClelland MR, Parick JH. Variations of gait parameters in Duchenne muscular dystrophy. Proc Inst Mech Eng. 1990;204:241–243
  35. Bakker JP, de Groot IJ, Beckerman H, et al. The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: Review of the literature. Clin Rehabil. 2000;14:343–359
  36. Muntoni F, Bushby K, Manzur A, et al. Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy 24 January 2005, London, UK. Neuromuscul Disord. 2006;16:210–219
  37. Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12:926–929
  38. Respiratory care of the patient with Duchenne muscular dystrophy (ATS Consensus Statement). Am J Respir Crit Care Med. 2004;170:456–465
  39. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics. 2005;116:1569–1573
  40. Bushby K, Muntoni F, Bourke JP. 107th ENMC International Workshop: The management of cardiac involvement in muscular dystrophy and myotonic dystrophy (7th-9th June 2002, Naarden, the Netherlands). Neuromuscul Disord. 2003;13:166–172
  41. Vestergaard P, Glerup H, Steffenson BF, et al. Fracture risk in patients with Duchenne muscular dystrophy and spinal muscular atrophy. J Rehabil Med. 2001;33:150–155
  42. Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatric Orthop. 2000;20:71–74
  43. Biggar WD, Bachrach LK, Henderson RC, et al. Bone Health in Duchenne muscular dystrophy: A workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord. 2005;15:80–85
  44. Quinlivan R, Roper H, Davie M, et al. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention Neuromuscul Disord. 2005;15:72–79
  45. Hawker GA, Ridout R, Harris VA, et al. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil. 2005;86:284–288

PII: S1071-9091(06)00130-6

doi: 10.1016/j.spen.2006.09.007

Seminars in Pediatric Neurology
Volume 13, Issue 4 , Pages 271-278 , December 2006

Article Tools

* Image Usage & Resolution